221 related articles for article (PubMed ID: 33092892)
1. Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells.
Stoica AF; Chang CH; Pauklin S
Trends Pharmacol Sci; 2020 Dec; 41(12):977-993. PubMed ID: 33092892
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
Nimmakayala RK; Leon F; Rachagani S; Rauth S; Nallasamy P; Marimuthu S; Shailendra GK; Chhonker YS; Chugh S; Chirravuri R; Gupta R; Mallya K; Prajapati DR; Lele SM; C Caffrey T; L Grem J; Grandgenett PM; Hollingsworth MA; Murry DJ; Batra SK; Ponnusamy MP
Oncogene; 2021 Jan; 40(1):215-231. PubMed ID: 33110235
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer stem cells: A state or an entity?
Hermann PC; Sainz B
Semin Cancer Biol; 2018 Dec; 53():223-231. PubMed ID: 30130664
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression.
Ogunleye AO; Nimmakayala RK; Batra SK; Ponnusamy MP
Stem Cells; 2023 May; 41(5):417-430. PubMed ID: 36869789
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
7. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment.
Sainz B; Alcala S; Garcia E; Sanchez-Ripoll Y; Azevedo MM; Cioffi M; Tatari M; Miranda-Lorenzo I; Hidalgo M; Gomez-Lopez G; Cañamero M; Erkan M; Kleeff J; García-Silva S; Sancho P; Hermann PC; Heeschen C
Gut; 2015 Dec; 64(12):1921-35. PubMed ID: 25841238
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes.
Marengo A; Forciniti S; Dando I; Dalla Pozza E; Stella B; Tsapis N; Yagoubi N; Fanelli G; Fattal E; Heeschen C; Palmieri M; Arpicco S
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):61-72. PubMed ID: 30267751
[TBL] [Abstract][Full Text] [Related]
9. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
11. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
12. Fetal bovine serum enlarges the size of human pancreatic cancer spheres accompanied by an increase in the expression of cancer stem cell markers.
Sasaki N; Toyoda M; Hasegawa F; Fujiwara M; Gomi F; Ishiwata T
Biochem Biophys Res Commun; 2019 Jun; 514(1):112-117. PubMed ID: 31027735
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment interactions with cancer stem cells in pancreatic ductal adenocarcinoma.
Palma AM; Bushnell GG; Wicha MS; Gogna R
Adv Cancer Res; 2023; 159():343-372. PubMed ID: 37268400
[TBL] [Abstract][Full Text] [Related]
14. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy.
Bhandari K; Ding WQ
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612768
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
16. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapeutics for Pancreatic Adenocarcinoma.
Lowery MA; O'Reilly EM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
[TBL] [Abstract][Full Text] [Related]
19. Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies.
Lonardo E; Cioffi M; Sancho P; Crusz S; Heeschen C
J Vis Exp; 2015 Jun; (100):e52801. PubMed ID: 26132091
[TBL] [Abstract][Full Text] [Related]
20. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
Gautam SK; Batra SK; Jain M
Mol Cancer; 2023 Jul; 22(1):118. PubMed ID: 37488598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
